Delving into the Latest Updates on Troikaa Pharmaceuticals Ltd. with Synapse

Overview

An Open Label, Balanced, Randomized, Single-Dose, Two-Treatment, Two-Sequence,Two-Period, Crossover, Comparative Bioavailability Study of Ketorolac TromethamineSublingual Tablet 10 mg of Troikaa Pharmaceuticals Ltd., India and Ketorol – DT(Ketorolac Tromethamine Dispersible Tablet 10 mg) of Dr. Reddys Laboratories Ltd.,India in healthy, adult, human subjects under fed condition. - NA

Start Date26 May 2024

Sponsor / Collaborator

Troikaa Pharmaceuticals Ltd.

CTRI/2024/04/066019 / CompletedPhase 4

A Prospective, Open-Label, randomized, Clinical study to compare the efficacy and safety of novel Methylcobalamin Nasal Spray with Sublingual Methylcobalamin Tablet in the treatment of subjects with vitamin B12 deficiency.

Start Date29 Apr 2024

Sponsor / Collaborator

Troikaa Pharmaceuticals Ltd.

CTRI/2023/06/054540 / CompletedNot Applicable

A randomized, open-label, two-treatment, two-period, two- sequence, single-dose,balanced, crossover, comparative bioavailability study of Dynapar QPS Plus of TroikaaPharmaceuticals Ltd., India with Volini Aerosol Spray of Sun Pharmaceutical IndustriesLtd, India in healthy, adult, human subjects under fasting conditions.

Start Date06 Jul 2023

Sponsor / Collaborator

Troikaa Pharmaceuticals Ltd.

100 Clinical Results associated with Troikaa Pharmaceuticals Ltd.

Login to view more data

0 Patents (Medical) associated with Troikaa Pharmaceuticals Ltd.

Login to view more data

21

Literatures (Medical) associated with Troikaa Pharmaceuticals Ltd.

30 Jun 2024·International journal of Pain

Response to Comments on “Superior Skin Penetration of Diclofenac from Dynapar QPS Plus as Compared to Diclofenac Aerosol Spray” by Mansuri et al.

Author: Prajapati, Kanaiyalal

31 Dec 2023·International journal of Pain

Superior Skin Penetration of Diclofenac from Dynapar QPS Plus as Compared to Diclofenac Aerosol Spray

Author: Agarwal, Vivek Kumar ; Patel, Sanjay B ; Zalavadiya, Sohin K ; Mansuri, Aamirraza ; Prajapati, Kanaiyalal D ; Patel, Ketan R

13 Sep 2020·Pharmaceutical Development and TechnologyQ4 · MEDICINE

Brain targeted delivery of lurasidone HCl via nasal administration of mucoadhesive nanoemulsion formulation for the potential management of schizophrenia

Q4 · MEDICINE

Article

Author: Patel, Rashmin B. ; Solanki, Ajay B. ; Thakore, Shivam D. ; Patel, Mrunali R.

This investigation aimed to design, develop, and optimize intranasal nanoemulsion for brain targeted delivery of lurasidone hydrochloride for the management and treatment of schizophrenia. The design of experiment supported optimization of high-pressure homogenization (HPH) process was executed for the manufacturing of lurasidone loaded nanoemulsion. The nanoemulsion comprising of lurasidone hydrochloride (10 mg/mL), 20% Oil_mix, 25% surfactant and, 55% aqueous phase (w/w) was processed with HPH at optimized conditions to get droplet size in the nano range. The droplet size of optimized nanoemulsion was found to be 48.07 ± 3.29 nm with a polydispersity index of 0.31 ± 0.01. The optimized translucent nanoemulsion (% transmittance of 88.56 ± 2.47) was found to be non-toxic to sheep nasal mucosa and stable for six months. The results of ex vivo diffusion study revealed the improvement in drug diffused by mucoadhesive nanoemulsion (MLNE) (1.41 × 10^-4 ± 1.11 × 10^-5 cm²/min) as compared to the solution (1.15 × 10^-4 ± 1.35 × 10^-5 cm²/min). The results of pharmacodynamic studies in mice uncover the highest inhibition of compulsive behavior (64.63%) and spontaneous locomotor activity (60.87%) shown by MLNE. This may be due to increased bioavailability in a brain, and possibly confirms the potential of nanoemulsion in targeting the brain through nasal route in the treatment of schizophrenia.

100 Deals associated with Troikaa Pharmaceuticals Ltd.

Login to view more data

100 Translational Medicine associated with Troikaa Pharmaceuticals Ltd.

Login to view more data